Aflibercept
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Aflibercept
- Aflibercept: From Metastatic Colorectal Cancer and Retinal Vascular Disease to Esotropia
Aflibercept: From Metastatic Colorectal Cancer and Retinal Vascular Disease to Esotropia
One-Sentence Summary
Aflibercept is a VEGF-trap protein originally used for retinal vascular diseases (macular degeneration, diabetic macular edema, retinal artery occlusion) and, in its intravenous form, for metastatic colorectal cancer. The TxGNN model predicts it may be effective for esotropia, but there are 0 clinical trials and 0 publications supporting this direction. The prediction is model-based only and has no supporting evidence in the data compiled for this report.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Metastatic colorectal cancer, macular degeneration, retinal artery occlusion, diabetic macular edema (from the knowledge graph; the Singapore licence records list no indication text) |
| Predicted New Indication | Esotropia |
| TxGNN Prediction Score | 99.38% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 4 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Aflibercept is a recombinant fusion protein that traps VEGF-A, VEGF-B and placental growth factor (PlGF). It is given by intravitreal injection for retinal vascular diseases and, as the product Zaltrap, by intravenous infusion for metastatic colorectal cancer. Detailed mechanism-of-action data from DrugBank are not currently available.
Esotropia is a disorder of ocular alignment, driven by neuromuscular or refractive factors. No plausible mechanistic link between VEGF blockade and esotropia has been identified. The two conditions share only the eye as an anatomical location. The very high TxGNN score is likely a knowledge-graph artifact, not a pharmacological signal.
Other top-ranked predictions are similarly weak. Examples include esophageal varices, urethral calculus, adenosine deaminase deficiency and hemorrhagic disease of the newborn. Several of these carry added safety concern, because anti-VEGF therapy is associated with bleeding risk. Some predicted tumours, such as ectomesenchymoma and middle ear neuroendocrine tumour, have a generic anti-angiogenic rationale, but no tumour-specific data were found.
Clinical Trial Evidence
Currently no related clinical trials registered for esotropia.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN17040P | EYLEA Solution for Injection in Vial 8 mg | Injection, solution | Not listed in the data |
| SIN14380P | EYLEA Solution for Injection in Prefilled Syringe 40 mg/ml | Injection, solution | Not listed in the data |
| SIN14592P | ZALTRAP Concentrate for Solution for Infusion 25 mg/ml | Infusion, solution concentrate | Not listed in the data |
| SIN14345P | EYLEA Solution for Injection in Vial 2 mg | Injection, solution | Not listed in the data |
Safety Considerations
- Drug Interactions: 78 interactions were identified. Major-level examples include deferiprone, samarium (153Sm) lexidronam, adalimumab, baricitinib, certolizumab pegol, cladribine and clozapine. Moderate-level examples include strontium chloride Sr-89, roflumilast, chloramphenicol, zidovudine, azathioprine, alemtuzumab and anakinra.
- Bleeding risk: Systemic anti-VEGF therapy is associated with bleeding and hemorrhage risk. This is particularly relevant to the bleeding-related predicted conditions.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for esotropia rests only on the model score. There are no clinical trials or literature, and no plausible mechanism links VEGF inhibition to ocular misalignment. Evidence is at level L5.
To proceed, the following is needed:
- A credible mechanistic hypothesis linking VEGF signalling to esotropia, supported by preclinical or observational data
- Detailed mechanism of action data (MOA)
- Package insert warnings and contraindications from the Singapore regulator (HSA) for the safety review
- Approved indication text for the Singapore registrations
- Review of the other top-ranked predictions, in particular the oncology candidates (ectomesenchymoma, malignant cutaneous granular cell tumour, middle ear neuroendocrine tumour), which have a more plausible anti-angiogenic rationale, and the bleeding-related conditions, which carry safety concerns
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.